XBiotech Inc. (XBIT)
NASDAQ: XBIT · Real-Time Price · USD
2.200
0.00 (0.00%)
Sep 8, 2026, 11:33 AM EDT - Market open
XBiotech Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | - | - | - | - | 4.01 | 18.39 |
| - | - | - | - | 4.01 | 18.39 | |
Revenue Growth | - | - | - | - | -78.20% | -58.19% |
Cost of Revenue | - | - | - | - | 0.65 | 5.82 |
Gross Profit | - | - | - | - | 3.36 | 12.57 |
Selling, General & Admin | 7.28 | 8.3 | 4.71 | 4.66 | 6.31 | 9.39 |
Research & Development | 40.94 | 47.39 | 37.76 | 32.85 | 31.54 | 28.27 |
Operating Expenses | 48.22 | 55.69 | 42.47 | 37.51 | 37.85 | 37.66 |
Operating Income | -48.22 | -55.69 | -42.47 | -37.51 | -34.49 | -25.08 |
Interest Expense | - | -0.09 | -0.81 | - | - | - |
Interest & Investment Income | 4.44 | 5.68 | 9.81 | 10.42 | 3.82 | 0.47 |
Currency Exchange Gain (Loss) | -2.58 | 3.33 | -5.53 | 1.89 | -2.8 | -0.71 |
Other Non Operating Income (Expenses) | 0.93 | 0.9 | 0.43 | 0.88 | -0.12 | -0.13 |
EBT Excluding Unusual Items | -45.42 | -45.86 | -38.56 | -24.31 | -33.59 | -25.46 |
Other Unusual Items | 0.56 | 0.56 | - | - | - | - |
Pretax Income | -44.86 | -45.31 | -38.56 | -24.31 | -33.59 | -25.46 |
Income Tax Expense | 0.27 | 0.24 | -0.03 | 0.24 | -0.69 | -8.04 |
Net Income | -45.13 | -45.54 | -38.53 | -24.56 | -32.9 | -17.41 |
Net Income to Common | -45.13 | -45.54 | -38.53 | -24.56 | -32.9 | -17.41 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 30 | 30 | 30 | 30 | 30 | 30 |
Shares Outstanding (Diluted) | 30 | 30 | 30 | 30 | 30 | 30 |
Shares Change | 0.04% | 0.09% | 0.07% | -0.00% | 1.32% | -2.53% |
EPS (Basic) | -1.48 | -1.49 | -1.26 | -0.81 | -1.08 | -0.58 |
EPS (Diluted) | -1.48 | -1.49 | -1.26 | -0.81 | -1.08 | -0.58 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -40.84 | -40.21 | -32.27 | -19.09 | -15.41 | 65.92 |
Free Cash Flow Per Share | -1.34 | -1.32 | -1.06 | -0.63 | -0.51 | 2.19 |
Gross Margin | - | - | - | - | 83.77% | 68.36% |
Operating Margin | - | - | - | - | -860.10% | -136.36% |
Profit Margin | - | - | - | - | -820.45% | -94.67% |
Free Cash Flow Margin | - | - | - | - | -384.26% | 358.38% |
EBITDA | -46.78 | -54 | -40.73 | -35.77 | -31.88 | -22.43 |
EBITDA Margin | - | - | - | - | - | -121.96% |
D&A For EBITDA | 1.44 | 1.69 | 1.75 | 1.74 | 2.61 | 2.65 |
EBIT | -48.22 | -55.69 | -42.47 | -37.51 | -34.49 | -25.08 |
EBIT Margin | - | - | - | - | - | -136.36% |
Revenue as Reported | - | - | - | - | 4.01 | 18.39 |